Skip to main content
All lobbying filings

THE CONSILIO GROUP

THE CONSILIO GROUP filed a Q3 report for N BRERETON MEDICAL TECHNOLOGIES on October 20, 2025, reporting $15,000 in lobbying income.

Lobbying for N BRERETON MEDICAL TECHNOLOGIES · Opiod prevention through a titration-based methodology.

All filings by THE CONSILIO GROUP · Everything N BRERETON MEDICAL TECHNOLOGIES has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Income
$15,000
What the client paid this registrant for the period.
Client based in
Virginia

Official filing document

 Lobbyists on this filing 2
  • OLIVER MEISSNER
    Previously held: CEO
  • BRANDON KIRBY
    Previously held: Director of Government Relations

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1

FenBlock is a patented, non-invasive medical device designed to help patients safely taper off prescribed fentanyl patches by gradually reducing the amount of medication absorbed through the skin.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem